Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:COGT NASDAQ:JANX NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.26-1.9%$3.06$1.05▼$3.97$368.43M2593,636 shs140,847 shsCOGTCogent Biosciences$12.67-1.2%$11.52$3.72▼$13.50$1.45B0.351.92 million shs461,929 shsJANXJanux Therapeutics$24.96+4.9%$24.57$21.97▼$71.71$1.51B2.84914,490 shs278,850 shsVERAVera Therapeutics$24.22-3.4%$22.25$18.53▼$51.61$1.55B1.171.37 million shs1.17 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-5.86%+6.85%+22.44%-6.98%+20.47%COGTCogent Biosciences+1.10%+6.83%+16.97%+76.58%+17.08%JANXJanux Therapeutics-4.15%+4.02%+4.16%-6.60%-43.18%VERAVera Therapeutics+1.33%+10.92%+26.73%+13.48%-34.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.26-1.9%$3.06$1.05▼$3.97$368.43M2593,636 shs140,847 shsCOGTCogent Biosciences$12.67-1.2%$11.52$3.72▼$13.50$1.45B0.351.92 million shs461,929 shsJANXJanux Therapeutics$24.96+4.9%$24.57$21.97▼$71.71$1.51B2.84914,490 shs278,850 shsVERAVera Therapeutics$24.22-3.4%$22.25$18.53▼$51.61$1.55B1.171.37 million shs1.17 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-5.86%+6.85%+22.44%-6.98%+20.47%COGTCogent Biosciences+1.10%+6.83%+16.97%+76.58%+17.08%JANXJanux Therapeutics-4.15%+4.02%+4.16%-6.60%-43.18%VERAVera Therapeutics+1.33%+10.92%+26.73%+13.48%-34.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75138.02% UpsideCOGTCogent Biosciences 2.92Moderate Buy$20.0057.85% UpsideJANXJanux Therapeutics 3.07Buy$80.92224.24% UpsideVERAVera Therapeutics 2.90Moderate Buy$63.00160.13% UpsideCurrent Analyst Ratings BreakdownLatest ADCT, VERA, COGT, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025JANXJanux TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.009/10/2025JANXJanux TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.009/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/2/2025COGTCogent BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$30.008/25/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.008/18/2025JANXJanux TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$42.008/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/7/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$29.00 ➝ $30.008/7/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$56.00 ➝ $53.008/6/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $21.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$77.25M4.74N/AN/A($2.10) per share-1.55COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AJANXJanux Therapeutics$10.59M141.61N/AN/A$19.49 per share1.28VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)COGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)Latest ADCT, VERA, COGT, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 million8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/A8/5/2025Q2 2025VERAVera Therapeutics-$0.82-$1.20-$0.38-$1.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66COGTCogent BiosciencesN/A4.194.19JANXJanux TherapeuticsN/A47.0347.03VERAVera Therapeutics0.1617.0317.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%COGTCogent BiosciencesN/AJANXJanux Therapeutics75.39%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%COGTCogent Biosciences7.29%JANXJanux Therapeutics29.40%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableVERAVera Therapeutics4063.82 million53.42 millionOptionableADCT, VERA, COGT, and JANX HeadlinesRecent News About These CompaniesSamlyn Capital LLC Sells 683,797 Shares of Vera Therapeutics, Inc. $VERASeptember 8 at 8:13 AM | marketbeat.comParkman Healthcare Partners LLC Acquires New Stake in Vera Therapeutics, Inc. $VERASeptember 8 at 7:45 AM | marketbeat.comCinctive Capital Management LP Cuts Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 8 at 5:47 AM | marketbeat.comVera Therapeutics, Inc. $VERA Stock Position Lifted by Trexquant Investment LPSeptember 8 at 3:51 AM | marketbeat.comNorthern Trust Corp Sells 36,748 Shares of Vera Therapeutics, Inc. $VERASeptember 8 at 3:21 AM | marketbeat.comVera Therapeutics, Inc. $VERA Shares Bought by EFG Asset Management North America Corp.September 6, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Consensus Price Target from BrokeragesSeptember 6, 2025 | americanbankingnews.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comVera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comFirst Light Asset Management LLC Sells 85,367 Shares of Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comVestal Point Capital LP Increases Stake in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Grows Position in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comMagnetar Financial LLC Takes Position in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 4, 2025 | marketbeat.comArmistice Capital LLC Grows Holdings in Vera Therapeutics, Inc. $VERASeptember 2, 2025 | marketbeat.comJump Financial LLC Invests $906,000 in Vera Therapeutics, Inc. $VERASeptember 2, 2025 | marketbeat.comTri Locum Partners LP Invests $3.61 Million in Vera Therapeutics, Inc. $VERAAugust 30, 2025 | marketbeat.comNuveen LLC Acquires New Position in Vera Therapeutics, Inc. $VERAAugust 30, 2025 | marketbeat.comWalleye Capital LLC Acquires New Stake in Vera Therapeutics, Inc. $VERAAugust 29, 2025 | marketbeat.comAmerican Century Companies Inc. Sells 51,490 Shares of Vera Therapeutics, Inc. $VERAAugust 29, 2025 | marketbeat.comVera Therapeutics, Inc. $VERA Shares Bought by Price T Rowe Associates Inc. MDAugust 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBJ’s Wholesale Club Pulls Back to Trend: It’s Time for an EntryBy Thomas Hughes | August 25, 2025Should You Join Buffett and Invest in Constellation Brands?By Jordan Chussler | August 22, 2025Monster Is Re-Energized: Can the Stock's Rally Continue?By Leo Miller | August 20, 2025NFL and WWE Land on ESPN—The Impact on Disney and TKO StocksBy Dan Schmidt | August 12, 2025Rocket Lab Strengthens Case for Breakout With New Launch PadBy Ryan Hasson | September 3, 2025ADCT, VERA, COGT, and JANX Company DescriptionsADC Therapeutics NYSE:ADCT$3.26 -0.06 (-1.93%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Cogent Biosciences NASDAQ:COGT$12.67 -0.15 (-1.17%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Janux Therapeutics NASDAQ:JANX$24.96 +1.18 (+4.95%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Vera Therapeutics NASDAQ:VERA$24.22 -0.86 (-3.43%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
